Period blood test could be alternative to cervical screening, study says.

A groundbreaking new study suggests that analyzing period blood could offer a highly accurate and significantly more convenient alternative to current cervical screening methods, potentially revolutionizing how cervical cancer is detected. The research, published in the esteemed journal The BMJ, highlights a promising development that could encourage greater participation in screening programs, particularly among women who currently avoid the conventional test.

The existing cervical screening process, a cornerstone of early detection for cervical cancer in the UK, involves a healthcare professional collecting cell samples directly from the cervix. While this method has proven effective, a concerning statistic reveals that approximately one-third of women invited for screening do not attend these appointments. This low uptake is attributed to a range of factors, including fear, pain, discomfort, and practical barriers, leading to a significant number of women missing potentially life-saving checks. In fact, recent research indicates that a staggering five million women are not up-to-date with their cervical screening appointments, underscoring the urgent need for more accessible and less intimidating alternatives.

The innovative approach explored in the study utilizes period blood collected on a simple cotton strip attached to a standard sanitary pad. This method allows for self-collection at home, offering a discreet and potentially less anxiety-inducing option for women. The implications of such a development are significant, especially for those who face particular challenges with traditional screening. As Athena Lamnisos from The Eve Appeal, a leading cervical cancer charity, points out, "Cervical screening can be difficult for some women for many reasons, like if they have had a bad previous experience, they are menopausal, they have a physical or learning disability, cultural barriers, or are a survivor of sexual violence." Data further indicates that younger women, individuals with disabilities, and those from ethnic minority communities and LGBT+ groups are disproportionately more likely to miss appointments, highlighting the inequity in current screening accessibility.

The study, conducted by Chinese researchers, involved over 3,000 women aged between 20 and 54 years. Participants collected period blood samples using the specialized sanitary pad system. These samples were then compared to those collected by clinicians using conventional methods. The findings were highly encouraging: testing period blood proved to be nearly as effective as traditional methods in identifying women with the disease and exceptionally good at correctly identifying those without it. The researchers emphasized the convenience of using menstrual blood for Human Papillomavirus (HPV) testing, noting that it respects women’s privacy and significantly reduces discomfort.

The National Health Service (NHS) in the UK is already taking steps to improve at-home screening options. In some areas of England, the NHS is distributing at-home test kits containing vaginal swabs to women who have missed multiple cervical screening appointments. These DIY kits are slated for wider rollout across the country later this year. Cervical screening appointments, offered every five years to all women and individuals with a cervix aged between 25 and 64 in the UK, primarily test for high-risk types of HPV, the virus strongly linked to the development of cervical cancer. The conventional screening procedure typically involves the insertion of a speculum into the vagina to gain access to the cervix, a process that can be uncomfortable or even distressing for some.

The potential of a period blood test as an alternative is being met with optimism by cervical cancer charities. They acknowledge the early stage of this research but are enthusiastic about the prospect of new, gentler testing methods that could improve access to screening. Sophie Brooks, health information manager at Cancer Research UK, described the research as "encouraging" and emphasized the importance of exploring novel approaches to enhance the accessibility of cervical screening. She highlighted the non-invasive nature of menstrual blood testing for HPV as a particularly interesting avenue but stressed the necessity of further research involving more diverse populations to determine its optimal integration into existing screening programs.

The period blood test, if further validated, could offer a significant advantage by being even less invasive than the current at-home swab kits. The Chinese researchers proposed it as a "robust alternative" to existing screening methods, noting its potential to increase screening rates by addressing some of the common barriers to attendance. For women who test positive for HPV through this method, the next step would be a colposcopy, a procedure where a specialized magnifying instrument is used to closely examine the cervix for any pre-cancerous cells.

However, experts caution that period blood tests are not an immediate replacement for current cervical screening. A key limitation is that only women who menstruate could utilize this method, excluding post-menopausal individuals and those who have undergone hysterectomies. Additionally, some researchers have raised concerns that the study might have overestimated the test’s performance because not all participants underwent a biopsy—a more detailed diagnostic test—to definitively confirm the results. This raises questions about the overall accuracy and reliability compared to established methods.

Despite these caveats, the potential benefits of a period blood test are substantial. Athena Lamnisos from The Eve Appeal expressed excitement about the prospect of new, more acceptable ways to offer a potentially life-saving test. She reiterated that individuals face diverse barriers and concerns regarding screening, and the availability of a choice of different methods could be profoundly beneficial for those who are eligible for screening but currently do not attend. This inclusivity and adaptability are crucial in the ongoing effort to reduce the incidence and mortality rates associated with cervical cancer. The development of such a test could represent a significant leap forward in preventative healthcare, making cervical cancer screening more approachable, equitable, and ultimately, more effective for a wider population.